Navigation Links
Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
Date:11/8/2007

at Administration (ACR Presentation 309)

The objective of the re-treatment study was to evaluate the safety, PD, PK and immunogenicity of TRU-015 for RA with repeated doses after receiving initial administration in a Phase I/IIa study. Patients treated with a single course of 5 mg/kg or higher in a previously conducted TRU-015 Phase I/IIa study were eligible for re-treatment. Patients who received a single infusion of 5 mg/kg received a single infusion of 5 mg/kg upon re-treatment, and those who received higher doses of TRU-015 received a single infusion of 15 mg/kg upon re-treatment. PD response of B-cells was also evaluated after initial treatment and after re-treatment.

Fifty-four patients were eligible for re-treatment, and at the time of this analysis, re-treatment data were available for 36 patients. B-cell depletion and recovery following re-treatment with TRU-015 was comparable to that seen after initial treatment. Ongoing patient evaluations showed maintenance of ACR responses with repeated single doses of TRU-015 at six-month intervals through at least two retreatment courses. Total serum IgG levels remained within normal limits. In addition, subjects treated with three or more courses of therapy experienced persistent decreases in rheumatoid factor and IgM levels without experiencing decreases in IgG or IgA levels. No neutralizing antibodies to TRU-015 had been detected at the time of this assessment.

Re-treatment with TRU-015 was generally well tolerated, and no grade 3 or 4 adverse events occurred on the day of infusion.

TRU-015 Clinical Development

Trubion and Wyeth have agreed on the design of the next clinical trial, and both companies are working to finalize protocol details and plans for study initiation. The randomized, double-blind, placebo-controlled, multicenter trial will examine ways to further optimize efficacy while evaluating dosing schedule. Additional study protocol details will be provided after commencemen
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , January 15, 2014 BreedIT Corp ... exclusive worldwide distributor of highly sophisticated agro-breeding solutions for ... 7, 2014, the Company,s board of directors appointed chemistry ... as its new member of the board. ...
(Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very ... King as its new Chief Executive Officer.  Mark was ... which he has overseen the company,s four facilities in ... Costa Rica.  Mr. King joined Tegra Medical in 2012 with ...
(Date:1/15/2014)... 2014 The Cadence Fitness & Health Center has ... Medical Fitness Association, a non-profit organization assisting medically integrated ... The Cadence Fitness & Health Center is the only ... in the Chicagoland area. "The certification means ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... N.J., Dec. 9, 2011 The Dr. Paul Janssen ... call for nominations. This prestigious award recognizes individuals ... potential to make, significant transformational contributions toward the ... www.pauljanssenaward.com and will be accepted until February ...
... of 94.4 out of 100, Elekta,s Leksell Gamma Knife® Perfexion™ ... among six advanced radiation therapy systems, according to KLAS research ... Dose of New Technology . The Elekta Infinity™ radiation ... of 84.4, improving its score over the 2010 report. ...
Cached Medicine Technology:Dr. Paul Janssen Award for Biomedical Research Issues Call for Nominations 2Dr. Paul Janssen Award for Biomedical Research Issues Call for Nominations 3Dr. Paul Janssen Award for Biomedical Research Issues Call for Nominations 4Elekta's Leksell Gamma Knife Perfexion Earns Nearly Perfect Score in 2011 KLAS Radiation Therapy Report 2
(Date:7/10/2014)... the "Mississippi baby" an infant seemingly cured of HIV ... remission of HIV infection in The New England Journal ... after more than two years of not taking antiretroviral therapy ... and researchers involved in the case. , "Certainly, ... child, the medical staff involved in the child,s care, and ...
(Date:7/10/2014)... research at the University of Huddersfield could help to ... emulsion-based food products such as butter, mayonnaise, yoghurt ... gain an international profile for her work. , Katerina ... at the University and now she has embarked on ... Dr Vassilis Kontogiorgos, she is investigating the potential of ...
(Date:7/10/2014)... with localized prostate cancer were more likely to ... less effective treatments and survived for shorter times ... a UCLA study has found. , The negative ... such as bias against the mentally ill, depression,s ... lack of investment in his general health and ...
(Date:7/9/2014)... 2014) If you think winning is one of the ... again: Winning along with other mental bonuses ranked near the ... into one of 11 big fun factors, according to a ... important when it comes to the "fun" factor, very little ... goes into this elusive conceptuntil now. , The results of ...
(Date:7/9/2014)... (PHILADELPHIA) Researchers at the Perelman School of Medicine ... Roswell Park Cancer Institute have received an $8 million ... the effects of photodynamic light therapy (PDT) in patients ... cancer that most often manifests itself in the lining ... exposure to asbestos. The grant will fund a clinical ...
Breaking Medicine News(10 mins):Health News:'Mississippi Baby' now has detectable HIV, researchers find 2Health News:'Mississippi Baby' now has detectable HIV, researchers find 3Health News:World interest in research work on the benefits of the Okra plant 2Health News:Depressed men with prostate cancer are diagnosed later stage, get less effective therapies 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3Health News:Penn mesothelioma program receives $8 million NCI grant 2
... 25, 2010 (Toronto) A new study from The Centre ... accounts for 43% of all cigarettes consumed by Ontario high ... The study, published in the current edition of Tobacco ... and found that of high school daily smokers, 50% smoked ...
... Amanda Gardner HealthDay Reporter , FRIDAY, Oct. 22 ... Staphylococcus aureus , or MRSA, a common bacterial infection acquired ... presented at the annual meeting of the Infectious Diseases Society ... of the people it infected within 30 days, the study ...
... DETROIT Patients admitted to the hospital for the ... a first line of defense with the potent antibiotic ... according to a Henry Ford Hospital study. For ... whether vancomycin or so-called B-lactam antibiotics like penicillin or ...
... Reporter , FRIDAY, Oct. 22 (HealthDay News) -- You might have seen ... an Iraq War vet with severe burns across much of his body ... his injuries. Martinez, 27, earned the right to play that role ... month into his first Iraq deployment as a real-life Army soldier, his ...
... School of Medicine, led by Lucila Ohno-Machado, MD, PhD, ... Department of Medicine, have received two federal grants totaling ... gather, analyze, use and share vast, ever-increasing amounts of ... over five years will create a national center for ...
... new cancer research being released at the American Society for ... 31 through November 4, 2010, in San Diego. For ... Napoli at nicolen@astro.org or Beth Bukata at ... 1:00 p.m. Eastern time. Adding radiation to hormone ...
Cached Medicine News:Health News:Contraband cigarettes main source of supply for Ontario youth 2Health News:MRSA Strain With Outbreak Potential Among Reports at Disease Conference 2Health News:MRSA Strain With Outbreak Potential Among Reports at Disease Conference 3Health News:Iraq War Vet, Daytime TV Star Turns Scars Into Inspiration 2Health News:Iraq War Vet, Daytime TV Star Turns Scars Into Inspiration 3Health News:UC San Diego receives 2 major biomedical informatics grants 2Health News:UC San Diego receives 2 major biomedical informatics grants 3Health News:UC San Diego receives 2 major biomedical informatics grants 4Health News:Practice-changing studies on how oncologists treat cancer to be presented at ASTRO Annual Meeting 2
Triangular 0.5 mm angled tip with 4 mm flat surface. Round knurled handle with dull finish. Tip angle: 150o....
Angled blade and flat serrated handle with polished finish. Blade: 1 mm x 10 mm....
Angled tip with gently curved blade. Short hexagonal handle with polished finish. 0.5 mm x 15 mm tip....
0.5 mm short 90 degree angled tip with black ebonized shaft. Titanium handle with position reference indicator. Shaft length 52 mm, handle length 100 mm....
Medicine Products: